Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Degarelix vs Leuprolide in Prostate Cancer (CS21)
NCT00295750Phase 3Completed
- Sponsor
- Ferring Pharmaceuticals
- Start
- Feb 2006
- Primary completion
- Oct 2007
- Modality
- Peptides, Small Molecules
- Countries
- 12
01
Overview
Phase 3, randomised, open-label trial of degarelix in prostate cancer (PCa) (3 arms), sponsored by Ferring Pharmaceuticals. Primary endpoint: Percentage of Patients With Testosterone <=0.5ng/mL From Day 28 Through Day 364. Started Feb 2006; status: completed.
02
Drugs
degarelix
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT00295750.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00295750.